DALLAS--(BUSINESS WIRE)--Kendall Law Group, led by former federal judge Joe Kendall, is investigating potential claims against the Board of Directors of BioMed Realty Trust, Inc. (NYSE: BMR) in connection with the proposed acquisition of BioMed by Blackstone Real Estate Partners VIII. According to the terms of the agreement, BioMed shareholders will receive $23.75 for each BioMed share held at the close of the transaction. At least one Wall Street analyst has placed a price target of BioMed at $26 per share, and BioMed has traded for more than $25/share this year.
The national securities firm’s investigation seeks to determine whether BioMed and its Board breached their fiduciary duties by engaging in self-dealing, failing to maximize the value of the Company, failing to disclose all material benefits and costs, and failing to obtain the best possible consideration for the shareholders. The Kendall Law Group is investigating whether BioMed shareholders have the option to file a lawsuit to ensure the board of directors obtains the best possible price for shareholders and the disclosure of material information.
If you currently own shares of BioMed and want to know more about your rights, you are encouraged to contact Jamie McKey at the Kendall Law Group at 877-744-3728 or by email at email@example.com to learn more about your rights as a shareholder. There is no cost or obligation to you. Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in nationwide complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.